HR
CSTL icon

Howe & Rusling’s Castle Biosciences CSTL Stock Holding History

Howe & Rusling’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-131
Closed -$3K – 484
2022
Q3 		$3K Buy
131
+46
+54% +$1.29K ﹤0.01% 775
2022
Q2 		$2K Buy
85
+60
+240% +$1.39K ﹤0.01% 853
2022
Q1 		$1K Sell
25
-8
-24% -$331 ﹤0.01% 922
2021
Q4 		$1K Hold
33
– – ﹤0.01% 919
2021
Q3 		$2K Buy
33
+9
+38% +$633 ﹤0.01% 833
2021
Q2 		$2K Buy
+24
New +$1.58K ﹤0.01% 789

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Howe & Rusling's CSTL Position: Q4 2022 in Review

Howe & Rusling sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 131 shares — an estimated $3K sold.

Howe & Rusling first reported a position in CSTL in Q2 2021 and held it in 6 quarters. The position peaked at $3K in Q3 2022. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Howe & Rusling reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 131 Castle Biosciences shares in Q4 2022, an estimated $3K.
  • Howe & Rusling first reported a position in Castle Biosciences in Q2 2021 and held it in 6 quarters.
  • Howe & Rusling's Castle Biosciences position peaked at $3K in Q3 2022.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.